A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

But patients would rather treat their sleep apnea with tirzepatide (Zepbound), a GLP-1 weight-loss drug, researchers found. "The results highlight a need for real-world comparative effectiveness ...

The Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

If you or a loved one has sleep apnea, you may be considering different treatment options. A new treatment you may hear about is Zepbound (tirzepatide). In December 2024, Zepbound became the ...

“This is a major step forward for patients with obstructive sleep apnea.” Ute Grabowsky/Photothek via Getty The FDA conducted two studies, both of which found that Zepbound helps reduce ...

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound ...